Hannah L. Archibald

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald et al. · Nature Medicine · 2016 · 999 citations · Full text

Medicine, Cancer Biology, Oncology +15

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi et al. · Nature · 2023 · 145 citations · Full text

Medicine, Cancer Biology, Molecular Genetics +12

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann et al. · Clinical Cancer Research · 2017 · 97 citations · Full text

Medicine, Cancer Biology, Oncology +10

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Varuna Nangia, Faria M. Siddiqui, Sean Caenepeel et al. · Cancer Discovery · 2018 · 91 citations

Medicine, Oncology, Pharmacology +15

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Aaron N. Hata, Steve Rowley, Hannah L. Archibald et al. · Oncogene · 2017 · 34 citations · Full text

Medicine, Molecular Biology, Oncology +16